Shortages. Claims for shortages in the amount of Products shipped by Patheon will be dealt with by reasonable agreement of the parties.
Shortages. 1. No employee may be required to make up cash register shortages unless he is given the privilege of checking the change and daily receipts upon starting and completing the work shift and unless the employee has exclusive access to the cash register during the work shift, except as specified below.
Shortages. 9.01 No employee may be disciplined for cash/bank account shortages unless they are assigned the responsibility of checking the money and daily receipts upon starting and completing their work shift and unless the employee has exclusive access to the cash/bank account during the work shift.
Shortages. BMS shall provide the Recipient with prompt notice of any Manufacturing and supply issues with respect to the BMS Study Drug that may adversely impact the conduct or timelines of the Combined Therapy Clinical Trial. In the event of a supply interruption or shortage of BMS Study Drug as determined by BMS pursuant to its internal processes and policies (a “Shortage”), such that BMS reasonably believes that it will not be able to fulfill its supply obligations under this Agreement, BMS will provide prompt written notice thereof to the Recipient (including the quantity of BMS Study Drug that BMS reasonably estimates it will be able to supply) and, upon request, the Parties will promptly discuss such situation (including how the quantities of BMS Study Drug that BMS is able to supply under this *CONFIDENTIAL TREATMENT REQUESTED. Agreement will be allocated within the Combined Therapy Clinical Trial). Notwithstanding anything to the contrary contained herein, in the event of a Shortage of the BMS Study Drug, BMS will have sole discretion, subject to Applicable Law, to determine the quantity of BMS Study Drug it will be able to supply as a result of such Shortage; provided, however, that BMS shall consider in good faith the needs of patients who are actively being treated with BMS Study Drug, including Combined Therapy Clinical Trial patients, in making such determination. BMS will not be deemed to be in breach of this Agreement for failure to supply any other quantities of BMS Study Drug hereunder as a result of a Shortage. Any such allocation of the BMS Study Drug in accordance with this Section 4.5 will be the Recipient’s exclusive remedy with respect to a Shortage.
Shortages. You must have a sufficient balance of funds on the Card at the time of a transaction in order to perform the transaction. If you attempt a Card transaction for an amount that is greater than the available balance on your Card, we have no obligation to approve that transaction, even if we previously have approved other insufficient funds transactions. In the event that we, in our sole discretion, settle or pay a transaction with your Card when there are insufficient funds stored on the Card to pay for the transactions, this will result in a negative funds balance on your Card. You agree to immediately pay us the amount of the negative funds balance without further demand by us, subject to the requirements of applicable law or regulation. We may deduct the amount of the negative balance from any funds loaded on to your Card, subject to the requirements of applicable law or regulation.
Shortages. Minor shortages will be paid the following pay period when brought to the attention of the Company. Shortages in excess of fifty dollars ($50.00) will be paid immediately.
Shortages. SYSCO and each Primary Distributor acknowledge that the designation of a SYSCO operating Company as a Primary Distributor limits the circumstances in which ARAMARK and participating ARAMARK Component will purchase from alternate suppliers. SYSCO, therefore, guarantees that each Primary Distributor will supply each participating ARAMARK Component with its entire order if product is available in the marketplace, provided that the participating ARAMARK Component's order is placed using a skip day ordering procedure.
Shortages. 27.01 Shortages that occur to non-public fund property stock or cash will be recovered in accordance with the following:
Shortages. Elan agrees that it will use commercially reasonable efforts to prevent an interruption of supply to Acorda and shall immediately notify Acorda of any problems or unusual production situations which may adversely affect production or quality of Product or its Specifications or its timely delivery to Acorda or its designee. If, at any time during the term of this Agreement, Elan becomes aware that it will not be able to satisfy Acorda’s forecasts or ordered requirements for Product, then Elan shall: (i) give Acorda prompt notice thereof, (ii) take all commercially reasonable steps to enable Acorda to procure adequate quantities of Product from the Second Source in accordance with the applicable provisions of Clause 7 and (iii) if such inability is partial, Elan shall fulfill firm orders with such quantities of Product as are available. and shall continue to use its commercially reasonable efforts to fulfill orders on a timely basis.
Shortages. Adolor shall give GSK written notice as soon as reasonably --------- practicable if Adolor becomes aware that its Product Suppliers will not be able to substantially satisfy the Parties' requirements for API Compound, and the Parties shall give each other written notice as soon as reasonably practicable if either Party becomes aware that its Product Suppliers will not be able to substantially satisfy the Parties' requirements for formulated Collaboration Products, for whatever reason. In the event that there is a failure to substantially satisfy the Parties' requirements of API Compound or formulated Collaboration Product, provided that such requirements cannot be satisfied by the Parties' inventories of API Compound or formulated Collaboration Product, and additionally provided that such failure will or does result in an interruption of supply of Collaboration Products to the commercial market, then GSK and Adolor will immediately work together, in good faith, to identify an appropriate alternative source of API Compound or formulated Collaboration Products supply, provided that:
